Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHE:300357
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 237 out of 850
Universe
Global Universe 8041 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Celldex Therapeutics, Inc. |
24.5
Medium
|
183 out of 850 |
BioCryst Pharmaceuticals, Inc. |
25.1
Medium
|
202 out of 850 |
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. |
25.7
Medium
|
237 out of 850 |
Ascentage Pharma Group International Co., Ltd. |
26.1
Medium
|
251 out of 850 |
InnoCare Pharma Ltd. |
30.4
High
|
508 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s Management of ESG Material Risk is Average